Covid-19 Vaccine stocks – which includes U.S.-listed pharma and biotech companies. The theme is up by about 640% year-to-date versus about 13% for the S&P 500.
[Updated 11/11/2020] Why Pfizer’s Vaccine Data Is Good News For Moderna
While Pfizer‘s (NYSE: PFE) surprisingly strong initial Covid-19 vaccine efficacy readout likely marks the beginning of the end of the Covid-19 pandemic, it probably doesn’t mean too much for Pfizer stock, given the limited potential profits and challenges with distribution. In fact, we think that the strong data from the vaccine – which is developed using messenger RNA (mRNA) technology could actually mean a lot more for Moderna (NASDAQ: MRNA), another Covid-19 vaccine player, whose entire drug pipeline is based on mRNA technology.
Last week, there were two positive developments relating to Pfizer (NYSE: PFE) and its German partner BioNTech’s Covid-19 vaccine, and one possible negative development. Firstly, Pfizer says based on internal testing that its vaccine can tolerate warmer temperatures than initially specified, possibly making it easier to handle and distribute. Under current protocol, the vaccine is being stored and transported at ultra-cold temperatures of -80 to -60 degrees Celsius until five days before use, calling for specialized equipment and a longer thawing period. However, the company is now asking the FDA to allow the shot to be stored for up to two weeks at -25 to -15 degrees Celsius, enabling the use of more standard freezers. This could make the shot more accessible in rural areas and emerging markets that don’t have special freezers. That said, rival Moderna’s shot is still easier to handle, as it can be stored at standard freezer temperatures for as long as six months and remain
Our indicative theme of Cybersecurity Stocks has returned over 150% since the end of 2019, compared to gains of about 21% on the S&P 500 over the same period. The theme is up by about 5% year-to-date.
Covid-19 Vaccine stocks – which includes U.S.-listed pharma and biotech companies. The theme is up by about 640% year-to-date versus about 13% for the S&P 500.
[Updated 11/11/2020] Why Pfizer’s Vaccine Data Is Good News For Moderna
While Pfizer‘s (NYSE: PFE) surprisingly strong initial Covid-19 vaccine efficacy readout likely marks the beginning of the end of the Covid-19 pandemic, it probably doesn’t mean too much for Pfizer stock, given the limited potential profits and challenges with distribution. In fact, we think that the strong data from the vaccine – which is developed using messenger RNA (mRNA) technology could actually mean a lot more for Moderna (NASDAQ: MRNA), another Covid-19 vaccine player, whose entire drug pipeline is based on mRNA technology.
Enphase Revenues have grown from about $286 million in 2017 to about $624 million in 2019, translating into a growth rate of about 48% each year. SolarEdge’s Revenues, which stand at more than double Enphase’s, have grown from about $607 million to about $1,426 million over the same period, a growth rate of about 53% per year. However, over the last 12 months, Enphase saw revenue rise by 42.1% – much higher than the figure of 19% for SolarEdge, as the company gained market share in the microinverter space. Enphase’s operating margin was 15.2% for the most recent twelve-month period, which is higher than SolarEdge Technologies’s operating margin of 13.2% over the same period. Enphase’s margins have also been trending higher, rising from 0.8% in 2018 to 15.2% over the last 12 months, while SolarEdge’s margins have declined slightly from 15% to 13.2%.